Resource Library

In multiple myeloma, the pace of therapeutic innovation is outstripping the speed of traditional clinical trial design. As CAR-T therapies, bispecific antibodies and earlier-line approvals redefine treatment pathways, comparator arms risk becoming obsolete before studies read out. The consequences are not academic: misaligned comparators can delay enrollment, trigger costly amendments, weaken regulatory confidence and erode commercial relevance.

 

This paper explores why comparator choice has become a defining strategic decision in myeloma development and outlines how integrating real-time field intelligence, regulatory insight and feasibility planning can help sponsors design trials that remain interpretable, executable and valuable as standards of care continue to shift in the multiple myeloma space.